Compare ABEO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABEO | RZLT |
|---|---|---|
| Founded | 1974 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 326.4M |
| IPO Year | 2005 | 2011 |
| Metric | ABEO | RZLT |
|---|---|---|
| Price | $5.34 | $3.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $20.00 | $9.67 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | 26.32 |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | $5.34 | ★ N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $1.07 |
| 52 Week High | $7.54 | $11.46 |
| Indicator | ABEO | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 52.75 |
| Support Level | $5.24 | $2.87 |
| Resistance Level | $5.62 | $3.73 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 55.38 | 40.34 |
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.